Oncolytics Biotech Inc ONCY.OQ ONCY.O is expected to show no change in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Oncolytics Biotech Inc is for a loss of 9 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Oncolytics Biotech Inc is $5.25, about 414.7% above its last closing price of $1.02
Previous quarterly performance (using preferred earnings measure in Canadian dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.10 | -0.10 | -0.14 | Missed | -44.8 |
Jun. 30 2025 | -0.15 | -0.11 | -0.07 | Beat | 34.4 |
Mar. 31 2025 | -0.09 | -0.10 | -0.08 | Beat | 20 |
Dec. 31 2024 | -0.13 | -0.12 | -0.10 | Beat | 18.2 |
Sep. 30 2024 | -0.10 | -0.10 | -0.12 | Missed | -17.8 |
Jun. 30 2024 | -0.10 | -0.10 | -0.10 | Met | 0.6 |
Mar. 31 2024 | -0.11 | -0.11 | -0.09 | Beat | 16.3 |
Dec. 31 2023 | -0.15 | -0.15 | -0.05 | Beat | 66.1 |
This summary was machine generated March 3 at 14:15 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments